Octreotide LAR: safety and tolerability issues
- 11 September 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 8 (6), 755-768
- https://doi.org/10.1517/14740330903379525
Abstract
Background: Somatostatin analogues are the cornerstone in therapy of acromegaly and functioning neuroendocrine tumors. Long-acting retard formulations have improved patient survival and contributed considerably to quality of life. The first such compound was octreotide LAR (‘long-acting release’), characterized by high affinity to somatostatin receptor subtypes 2 and 5, which has to be injected intramuscularly every 4 weeks. Objective: The aim was to screen all octreotide LAR-related literature and assess the compound's profile for safety and tolerability. Methods: An extensive literature search has been performed using the MEDLINE database to retrieve data from clinical studies evaluating the efficacy and tolerability of octreotide LAR. Results/conclusion: Octreotide LAR is well tolerated; however, diarrhea and gallstone formation were identified as the main adverse events. Impairment of glucose homeostasis was a regular phenomenon, but its occurrence was unpredictable. General side effects such as headache, abdominal discomfort or fatigue were also reported. According to incidental case reports, administration during pregnancy appears to be safe for both mother and child; however, definitive evidence is missing. In addition, octreotide LAR has been evaluated for further indications including treatment of solid tumor entities, due to its antiproliferative effect. Currently, several compounds (lanreotide, SOM230) with a broader receptor spectrum are under evaluation and may improve treatment efficacy and lower incidence of side effects.Keywords
This publication has 99 references indexed in Scilit:
- Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre studyClinical Endocrinology, 2009
- Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell linesCancer, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgeryTechniques in Coloproctology, 2006
- Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotideBritish Journal of Cancer, 2006
- Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatmentClinical Endocrinology, 2003
- Pharmacokinetics, Pharmacodynamics, and Safety of Microencapsulated Octreotide Acetate in Healthy SubjectsThe Journal of Clinical Pharmacology, 2000
- Maternal–Fetal Transfer of OctreotideThe New England Journal of Medicine, 1995
- Somatostatinoma SyndromeThe New England Journal of Medicine, 1979
- “Somatostatinoma”: A Somatostatin-Containing Tumor of the Endocrine PancreasThe New England Journal of Medicine, 1977